Characterized by its capacity to induce organ failure, sepsis constitutes a life‐threatening pathological state with high incidence and mortality rates. Current treatments primarily focus on antimicrobial therapy and organ support, lacking direct interventions targeting the restoration of cellular or organelle function. Among these mechanisms, mitochondrial dysfunction and overactivation of the NLR family pyrin domain‐containing 3 (NLRP3) inflammasome stand out as key pathological hallmarks. As a classic inflammasome, the NLRP3 inflammasome, upon activation, drives cellular pyroptosis and massive release of inflammatory mediators. Beyond their role as cellular energy generators, mitochondria participate in the modulation of inflammatory responses and oxidative stress control. Mitochondrial quality control (MQC) serves as a prerequisite for the orderly performance of mitochondrial physiological functions. Disruption of MQC invariably results in mitochondrial dysfunction, triggering liberation of mitochondrial reactive oxygen species (mtROS) along with mitochondrial damage‐associated molecular patterns (mtDAMPs), which serve as direct triggers for NLRP3 inflammasome formation and stimulation. This process disrupts MQC, exacerbates mitochondrial dysfunction, and forms a mutually reinforcing “MQC imbalance‐NLRP3 overactivation” vicious cycle that drives disease progression. This review aims to: (1) systematically elucidate the complex bidirectional regulatory mechanisms between the NLRP3 inflammasome and MQC in the context of sepsis, (2) summarize the latest research progress on targeted intervention strategies based on this vicious cycle, and (3) discuss the challenges in clinical translation and future directions of these strategies.
Sepsis-induced acute kidney injury (S-AKI) is a common complication of sepsis. It occurs at high incidence and is associated with a high level of mortality in the intensive care unit (ICU). The pathophysiologic mechanisms underlying S-AKI are complex, and include renal vascular endothelial cell dysfunction. The endothelial glycocalyx (EG) is a polysaccharide/protein complex located on the cell membrane at the luminal surface of vascular endothelial cells that has anti-inflammatory, anti-thrombotic, and endothelial protective effects. Recent studies have shown that glycocalyx damage plays a causal role in S-AKI progression. In this review, we first describe the structure, location, and basic function of the EG. Second, we analyze the underlying mechanisms of EG degradation in sepsis and S-AKI. Finally, we provide a summary of the potential therapeutic strategies that target the EG.
Sepsis is a life‑threatening organ dysfunction disorder caused by dysfunctional host response to infection. Sepsis‑induced cardiomyopathy (SIC) is a common and serious complication of sepsis, and it is associated with increased mortality rates; however, its specific pathogenesis is still unclear. Ferroptosis, which is an iron‑dependent form of programmed cell death, is involved in the pathophysiology of SIC. Further study on the mechanism and therapeutic targets of ferroptosis in SIC may provide new strategies for clinical diagnosis and treatment of this condition. The present article reviews the mechanisms between SIC and ferroptosis, summarizes the progress in research of the involvement of ferroptosis in SIC and provides new potential strategies for further research and treatment in the future.
Sepsis is a systemic inflammatory disorder characterized by multi‑organ dysfunction following infection. Sepsis‑induced cardiomyopathy (SIC) represents a prevalent complication that markedly contributes to in‑hospital mortality. The NOD‑like receptor protein 3 (NLRP3) inflammasome serves as an important regulator in SIC pathogenesis, directly impairing cardiac function through multiple mechanisms: i) Driving cytokine storms; ii) inducing cardiomyocyte pyroptosis and apoptosis; iii) disrupting mitochondrial homeostasis; and iv) suppressing autophagy. Molecularly‑targeted NLRP3 inhibitors have been developed, such as MCC950, curcumin, indole‑3‑propionic acid and carvacrol, which have demonstrated cardioprotective effects in cellular and animal models of SIC. Further exploration of NLRP3 mechanisms and resulting therapeutic targets may yield novel strategies for SIC diagnosis and clinical management. The present review examined NLRP3‑mediated pathways involving inflammation, programmed cell death and mitophagy in SIC pathogenesis, summarized pharmacological interventions targeting these pathways and highlighted previous advances in NLRP3 research to inform future therapeutic development and clinical translation.
29 April 2022 in Journal of Cardiothoracic and Vascular Anesthesia